investigational compound

Related by string. Investigational Compound * Investigational : Investigational Device Exemption IDE . investigational compounds . Investigational Device Exemption . investigational therapies . Investigational NDAs . investigational mTOR inhibitor / Compound . COMPOUND : bin Laden compound . heavily fortified compound . mud walled compound . Branch Davidian compound . compound fracture * *

Related by context. Frequent words. (Click for all words.) 72 investigational drug 68 Phase 2b clinical 68 oral formulation 67 Phase 2a clinical 67 investigational 67 Phase IIa trial 67 Phase IIa clinical 67 orally administered 66 Perifosine 66 Phase III clinical 66 Phase 2b study 65 humanized monoclonal antibody 65 Phase IIb clinical 65 receptor antagonist 65 Phase 2b trial 65 JANUVIA 64 Phase Ib 64 Marqibo 64 relapsing remitting multiple sclerosis 64 perifosine 64 IMGN# 64 pivotal Phase III 64 carfilzomib 64 Phase IIb trial 64 kinase inhibitor 64 prodrug 64 disease modifying 63 receptor agonist 63 daclizumab 63 Phase 2a 63 RG# [001] 63 selective inhibitor 63 ISIS # 63 RDEA# 63 AZD# 63 AEZS 62 NKTR 62 PRX # 62 CRx 62 Alpharadin 62 Clolar 62 Phase IIa 62 MGCD# [001] 62 AP# [003] 62 T DM1 61 Phase III clinical trials 61 linaclotide 61 tablet formulation 61 monotherapy 61 Phase 2b 61 ofatumumab 61 Satraplatin 61 satraplatin 61 Zerenex 61 preclinical studies 61 laquinimod 61 Phase IIb 61 cutaneous T cell 61 tolerability 61 INCB# [002] 61 Phase 1b 60 telbivudine 60 maraviroc 60 sunitinib 60 lapatinib 60 clinical trial 60 raltegravir 60 hormone refractory prostate cancer 60 tamibarotene 60 tolerability profile 60 FTY# 60 chronic lymphocytic leukemia CLL 60 APD# 60 Phase III trials 60 clofarabine 60 pharmacokinetic profile 59 pivotal Phase 59 vilazodone 59 ADX# 59 FOLOTYN 59 Phase III 59 Afinitor 59 sitagliptin 59 protease inhibitor 59 LymphoStat B 59 APF# 59 SEROQUEL 59 sNDA 59 mg dose 59 mipomersen 59 VELCADE 59 dasatinib 59 pralatrexate 59 milnacipran 59 XL# [003] 59 granted orphan 59 Bronchitol 59 dose escalation study 59 sorafenib 59 intravenous formulation 58 ACTEMRA

Back to home page